 임세진 교수 E-mail : sejinim@skku.edu |
|
연구분야 1. 종양, 감염, 이식편대 숙주질환 모델에서 T세포 분화기전에 관한 연구 2. 신규 면역치료제 개발 a. 신규 면역조절단백질 발굴 및 이에 대한 항체 치료제 개발 b. 암환자 내인성 T세포 이용한 역분화 T세포 치료제 개발 3. 암환자에서 면역관문억제제 치료반응성 예측 바이오마커 발굴 |
|
학력사항 2000-2003 포항공과대학교 생명과학과, 학사 2003-2012 포항공과대학교 생명과학과, 박사 |
|
경력사항 2012-2019 에모리대학교 미생물 및 면역학과, 박사후 / 책임 / 수석연구원 2020-present 성균관대학교 의과대학, 조교수 / 부교수 2021-present 실험혈액학회 이사 2022-present 대한면역학회 국제협력위원회 위원 2023-2024 대한면역학회 학술위원회 위원 2024-present 대한암학회 학술위원회 위원 2024-present 대한암학회 연구위원회 위원 2022 포스코사이언스 펠로 2024 대한면역학회-씨젠의료재단 학술우수상 2025 제4회 임성기과학재단 젋은연구자상 |
|
주요 연구물 1. *Im SJ, Lee K, and *Ha SJ. Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends. Exp Mol Med (2024) 56(9): 1900 (Review) PMID: 39218982 (IF: 12.8) (*Co-corresponding authors) 2. Lee S, Ko Y, Lee HW, Oh WJ, Hong HG, Ariyaratne D, *Im SJ, and *Kim TJ. Two distinct subpopulations of marginal zone B cells exhibit differential antibody-producing capacities and radioresistance. Cell Mol Immunol (2024) 21(4): 393 PMID: 38424169 (IF: 24.1) (*Co-corresponding authors) 3. *Lee S, *Lee Ku, Bae H, Lee Ky, Lee J, Ma J, Lee YJ, Lee BR, Park W-Y, and Im SJ. Defining a TCF1-expressing progenitor allogeneic CD8+ T cell subset in acute graft-versus-host disease. Nat Comm (2023) 14(1): 5869 PMID: 37737221 (IF: 17.694) (*Co-first authors) 4. *,☨Im SJ, *Obeng RC, Nasti TH, McManus D, Kamphorst AO, Sunisetty S, Prokhnevska N, Carlisle JW, Yu K, Sica GL, Cardozo LE, Goncalves AN, Kissick HT, Nakaya HI, ☨Ramalingam SS, and ☨Ahmed R. Characteristics and anatomic location of PD-1+TCF1+ stem-like CD8 T cells in chronic viral infection and cancer. Proc Natl Acad Sci USA (2023) 120(41): e2221985120 PMID: 37782797 (IF: 12.779) (*Co-first authors, ☨Co-corresponding authors) 5. *Lee J, *Lee K, Bae H, Lee K, Lee S, Ma J, Jo K, Kim I, Lee B, Kang M, and Im SJ. IL-15 promotes self-renewal of progenitor exhausted CD8 T cells during persistent antigenic stimulation. Front Immunol (2023) 14: 1117092 PMID: 37409128 (IF: 8.787) (*Co-first authors) 6. Jeong SM, Jin E-J, Wei S, Bae J-H, Ji Y, Jo Y, Jeong J-H, *Im SJ, and *Ryu D. The impact of cancer cachexia on gut microbiota composition and short-chain fatty acid metabolism in a murine model. BMB reports (2023) 56(7): 404 PMID: 37220908 (IF: 5.041) (*Co-corresponding authors) 7. Lee S, Ma J, and Im SJ. Expression and function of CD51 on CD8 T cells as an immunomodulatory target. Biochem Biophys Res Commun. (2023) 661: 56 PMID: 37087799 (IF: 3.322) 8. Im SJ, Konieczny BT, Hudson WH, Masopust D and Ahmed R. PD-1+ stemlike CD8 T cells are resident in lymphoid tissues during persistent LCMV infection. Proc Natl Acad Sci USA (2020) 117(8):4292 PMID: 32034098 (IF: 9.504) 9. *Jadhav RR, *Im SJ, *Hu B, Hashimoto M, Li P, Leonard WJ, Greenleaf WJ, ☨Ahmed R and ☨Goronzy JJ. Epigenetic signature of PD-1+TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade. Proc Natl Acad Sci USA (2019), 116 (28):14113 PMID: 31227606 (IF: 9.504) (*Co-first authors, ☨Co-corresponding authors) 10.Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q, Hale JS, Lee J, Nasti TH, Sharpe AH, Freeman GJ, Germain RN, Nakaya HI, Xue HH and Ahmed R. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature (2016) 537(7620):417. PMID: 27501248 (IF: 40.137) - This article is highlighted in News and Views of same issue of Nature (2016) 537(7620):312. |
